We provide innovative devices, drugs, diagnostic reagents and services to improve the preservation, evaluation and transportation of transplanted organs, help transplant patients survive for a long time, and promote innovation and development in the field of transplantation.
The company was founded in 2004 with a registered capital of RMB 70.4 million and 194 employees worldwide, including 46 R&D staff members.
The company focuses on organ transplantation as a provider of medical products and professional services for the global market around the entire transplant process.
Focusing on the needs of organ transplantation surgeons and patients, we provides medical devices and professional services related to organ transplantation, mainly involving products for the preservation, transportation, evaluation and repair of transplanted organs and in vitro diagnostic reagents for individualized and precise diagnosis of transplant patients, which are exported to about 46 countries and regions worldwide.
-Starting distribution of over- seas transplant products ·
-Covering the transplant
market in East China
-Set up manufacturing plant in Yunze IVD subsi- diary
- Completed LSI M&A
-Expanding to global market
• Received China NMPA approval for the first independently developed product G16
-Received FDA approval for G16
- Genext Founded
- Acting as Hisun exclusive distributor of immunosup- pressant to expand national sales
-Listed on China OTC market
-New R&D center established
-Received CE certification for all TDM products
Asia: China, Philippines, Thailand, Singapore, India, South Korea
Europe: Austria, Belgium, Croatia, Czech Republic, Denmark, England, Estonia, France, Germany, Ireland, Italy, Latvia, Lithuania, Norway, Northern Ireland, Poland, Portugal, Romania, Scotland, Slovenia, Spain, Sweden, Switzerland, Netherlands, Wales, Turkey, Polynesia
North America: United States, Canada, Panama
South America: Brazil, Colombia, Peru, Argentina, Mexico
Middle East: Israel, Kuwait, Saudi Arabia
Africa: Algeria
Oceania: Australia
Genext focuses on human organ transplantation. Leveraging on innovative technologies and services, the company hopes to help physicians and patients improve the long-term survival.
The company was founded in 2004 with a registered capital of RMB 70.4 million and 194 employees worldwide, including 46 R&D staff members. The company focuses on organ transplantation as a provider of medical products and professional services for the global market around the entire transplant process. Focusing on the needs of organ transplantation surgeons and patients, we provides medical devices and professional services related to organ transplantation, mainly involving products for the preservation, transportation, evaluation and repair of transplanted organs and in vitro diagnostic reagents for individualized and precise diagnosis of transplant patients, which are exported to about 46 countries and regions worldwide.
